Orchard Therapeutics plc
DelistedCIK 1748907fmd_1GKDRC6CDF6H2FVS7NJH3B8YA4Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2016 to Sep 30, 2023, 25 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 2 | 3 | 3 | 2 | 23 |
| Cost of revenue | – | – | 0 | 1 | 1 | 0 | 7 |
| Gross profit | – | – | 2 | 2 | 2 | 1 | 16 |
| Research and development | 16 | 33 | 205 | 117 | 94 | 87 | 94 |
| Selling, general and administrative | 3 | 6 | 31 | 57 | 65 | 55 | 49 |
| Operating income | (19) | (39) | (235) | (173) | (157) | (140) | (127) |
| Interest expense | – | – | – | 2 | 2 | 2 | 3 |
| Interest and investment income | – | – | 1 | 7 | 3 | 0 | 2 |
| Other non-operating income (expense) | 0 | (1) | 6 | 7 | 4 | (3) | (26) |
| Income before taxes | (19) | (40) | (230) | (166) | (153) | (144) | (153) |
| Income tax expense | 0 | 0 | 1 | (2) | (1) | 1 | (2) |
| Net income from continuing operations | (19) | (40) | (231) | (163) | (152) | (145) | (151) |
| Net income | (19) | (40) | (230) | (163) | (152) | (145) | (151) |
| Net income to common shareholders | (19) | (40) | (230) | (163) | – | – | – |